No IRA Pill Penalty Changes in Trump’s Tax Bill Passed by Congress
TL/DR –
The US House of Representatives passed President Donald Trump’s tax reform bill, known as the “One Big Beautiful Bill Act”, in a 215-214 vote, with the legislation now set to advance to the Senate. Key features of the bill include modifications to the drug price negotiation program created under the Inflation Reduction Act, such as the exclusion of orphan drugs approved to treat more than one rare disease from negotiations. Meanwhile, the White House unveiled its MAHA report, outlining health policy priorities and addressing issues such as overmedicalisation of children and corporate influence over health systems.
The House of Representatives Approves President Trump’s Tax Reform Bill
By a tight vote of 215–214, the House of Representatives passed President Trump’s comprehensive tax reform bill. The bill, known as the “One Big Beautiful Bill Act“, alters the Biden-era drug price negotiation program and now moves to the Senate.
Details of the One Big Beautiful Bill Act
The Act proposes to exclude certain orphan drugs from negotiation and limits the practice of spread-pricing by pharmacy benefit managers. However, the act lacks adjustments to the pill penalty, which Trump previously supported removing with an executive order.
MAHA Report Released
Alongside this, the White House published a 70-page MAHA report, detailing policy priorities for the Department of Health and Human Services. The report aims to address the “childhood chronic disease crisis” and help the government transform the U.S. food, health, and scientific systems.
Concerns Highlighted in MAHA Report
The report criticizes the overmedicalization of children, blaming conflicts of interest in medical research, regulation, and practice. It accuses the pharma industry of corporate capture and exacerbating threats to American childhood through their influence over regulatory bodies.
Recommendations of the MAHA Report
The report recommends initiatives like a robust post-marketing surveillance mechanism for real-world safety findings and supporting studies assessing long-term outcomes of common drugs prescribed for children.
—
Read More US Economic News